Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension

Laurent Savale; Ly Tu; Corinne Normand; Athénaïs Boucly; Olivier Sitbon; David Montani; Karen M Olsson; Da-Hee Park; Jan Fuge; Jan C Kamp; Marc Humbert; Marius M Hoeper; Christophe Guignabert

doi:10.1183/13993003.01483-2024

Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension

Eur Respir J. 2024 Oct 31;64(4):2401483. doi: 10.1183/13993003.01483-2024. Print 2024 Oct.

Authors

Laurent Savale^{1

2

3}, Ly Tu^{1

2}, Corinne Normand^{1

2}, Athénaïs Boucly^{1

2

3}, Olivier Sitbon^{1

2

3}, David Montani^{1

2

3}, Karen M Olsson⁴, Da-Hee Park⁴, Jan Fuge⁴, Jan C Kamp⁴, Marc Humbert^{1

2

3}, Marius M Hoeper⁴, Christophe Guignabert^{5

2}

Affiliations

¹ Université Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France.
² INSERM UMR_S 999, HPPIT, Le Kremlin-Bicêtre, France.
³ Department of Respiratory and Intensive Care Medicine, Assistance Publique Hôpitaux de Paris, Hôpital Bicêtre, ERN-LUNG, Le Kremlin-Bicêtre, France.
⁴ Department for Respiratory Medicine and Infectious Diseases and German Centre of Lung Research (DZL), Hannover Medical School, Hannover, Germany.
⁵ Université Paris-Saclay, Hypertension Pulmonaire: Physiopathology and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France [email protected].

Abstract

Proteomic analysis of circulating biomarkers reveals that sotatercept's impact extends beyond activins to influence BMP-9 and BMP-10, along with essential metabolic and inflammatory factors https://bit.ly/3Z5AZJ3

Publication types

Letter